Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
e-PREDICE: Linagliptin and Metformin for Prevention of Diabetes Complications
NCT03222765Phase 3Unknown
- Sponsor
- Evidem Consultores
- Start
- Mar 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linagliptin in prediabetes (4 arms), sponsored by Evidem Consultores. Primary endpoints: Microvascular Complication Index at 2 years, Diabetic Retinopathy Scale ETDRS at 2 years and 2 more. Status: unknown.
02
Drugs
linagliptin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT03222765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222765.